The application of human phase 0 microdosing trials: A systematic review and perspectives

Pernille Svendsen(Aalborg University Hospital), Hans Erik Johnsen(Herlev Hospital), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Maria Bach Laursen(Chr. Hansen (Denmark)), Paw Jensen(Aalborg University Hospital), Martin Bøgsted(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital)

Leukemia & lymphoma/Leukemia and lymphoma

October 2, 2015

10.3109/10428194.2015.1101097

Cited by 10

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

|Leukemia|2015|256